RPL31P9

Across TCGA pan-cancer cohorts, RPL31P9 RNA is linked to patient survival in 8 of 34 cancer types, making it the most broadly survival-associated RPL31P9 data layer.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher RPL31P9 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated RPL31P9 expression acts as an unfavorable survival marker.

STAD, READ, and MESO are the cancer types where RPL31P9 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	OS	Tertile	All	0.404	0.595	.004	60	view →
READ	OS	Tertile	IV	0.289	0.899	<.001	54	view →
MESO	OS	Tertile	All	0.144	0.557	.029	45	view →
SKCM	DFS	Tertile	All	0.058	0.757	<.001	42	view →
KIRC	DFS	Tertile	IV	0.127	0.630	.039	18	view →
COAD	OS	Tertile	III,IV	0.157	0.791	.001	18	view →
PRAD	OS	Tertile	All	0.909	0.990	.001	12	view →
GBM	OS	Tertile	All	0.119	0.421	.019	9	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

RPL31P9–STAD (OS)

Open the STAD breakdown →